WO2023156807A3 - Prevention and treatment of diseases by modulating activity of mesenchymal stem cells with p62 (sqstm1)-encoding vector and pharmaceutical formulations containing p62 (sqstm1) proteins - Google Patents

Prevention and treatment of diseases by modulating activity of mesenchymal stem cells with p62 (sqstm1)-encoding vector and pharmaceutical formulations containing p62 (sqstm1) proteins Download PDF

Info

Publication number
WO2023156807A3
WO2023156807A3 PCT/IB2022/000623 IB2022000623W WO2023156807A3 WO 2023156807 A3 WO2023156807 A3 WO 2023156807A3 IB 2022000623 W IB2022000623 W IB 2022000623W WO 2023156807 A3 WO2023156807 A3 WO 2023156807A3
Authority
WO
WIPO (PCT)
Prior art keywords
sqstm1
proteins
treatment
prevention
diseases
Prior art date
Application number
PCT/IB2022/000623
Other languages
French (fr)
Other versions
WO2023156807A2 (en
Inventor
Alexander SHNEIDER
Dimitrios AGAS
Vladimir Gabai
Albert A. SUFIANOV
Maria Giovanna SABBIETI
Original Assignee
Curelab Oncology, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curelab Oncology, Inc. filed Critical Curelab Oncology, Inc.
Priority to AU2022441199A priority Critical patent/AU2022441199A1/en
Publication of WO2023156807A2 publication Critical patent/WO2023156807A2/en
Publication of WO2023156807A3 publication Critical patent/WO2023156807A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Utilizing a p62/SQSTM1 -encoding vector and/or a pharmaceutical formulation containing p62/SQSTM1-proteins (collectively, p62) to modulate the activity of MSCs which would lead to disease prevention and/or treatment. The p62 may be used to pulse isolated MSCs, which can be later administered to a patient as cell therapy, or p62 can be administered to a patient and modulate MSCs inside the patient's body.
PCT/IB2022/000623 2021-09-27 2022-09-27 Prevention and treatment of diseases by modulating activity of mesenchymal stem cells with p62 (sqstm1)-encoding vector and pharmaceutical formulations containing p62 (sqstm1) proteins WO2023156807A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022441199A AU2022441199A1 (en) 2021-09-27 2022-09-27 Prevention and treatment of diseases by modulating activity of mesenchymal stem cells with p62 (sqstm1)-encoding vector and pharmaceutical formulations containing p62 (sqstm1) proteins

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163248555P 2021-09-27 2021-09-27
US202163249022P 2021-09-27 2021-09-27
US63/248,555 2021-09-27
US63/249,022 2021-09-27

Publications (2)

Publication Number Publication Date
WO2023156807A2 WO2023156807A2 (en) 2023-08-24
WO2023156807A3 true WO2023156807A3 (en) 2023-09-28

Family

ID=87579169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2022/000623 WO2023156807A2 (en) 2021-09-27 2022-09-27 Prevention and treatment of diseases by modulating activity of mesenchymal stem cells with p62 (sqstm1)-encoding vector and pharmaceutical formulations containing p62 (sqstm1) proteins

Country Status (2)

Country Link
AU (1) AU2022441199A1 (en)
WO (1) WO2023156807A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108354941A (en) * 2018-02-26 2018-08-03 南京工业大学 A kind of application of natural products small molecule alpha-arbutin (Arb) in preventing Parkinson disease drug
US20190153056A1 (en) * 2013-12-29 2019-05-23 Curelab Oncology, Inc. Methods and compositions relating to p62/SQSTM1 for the treatment and prevention of inflammation-associated diseases
WO2020160468A1 (en) * 2019-02-01 2020-08-06 Avrobio, Inc. Compositions and methods for treating neurocognitive disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190153056A1 (en) * 2013-12-29 2019-05-23 Curelab Oncology, Inc. Methods and compositions relating to p62/SQSTM1 for the treatment and prevention of inflammation-associated diseases
CN108354941A (en) * 2018-02-26 2018-08-03 南京工业大学 A kind of application of natural products small molecule alpha-arbutin (Arb) in preventing Parkinson disease drug
WO2020160468A1 (en) * 2019-02-01 2020-08-06 Avrobio, Inc. Compositions and methods for treating neurocognitive disorders

Also Published As

Publication number Publication date
AU2022441199A1 (en) 2024-05-16
WO2023156807A2 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
CN104662007B (en) Cystathionine gamma lyase (CSE) inhibitor
ES2278393T3 (en) ANTIMICROBIAL TREATMENT OF VIRUS HERPES SIMPLEX AND OTHER INFECTIOUS DISEASES.
US9808491B2 (en) Compositions of morselized umbilical cord and/or amniotic membrane and methods of use thereof
IN2015DN01616A (en)
BRPI0411856A (en) compositions and methods for increasing telomerase activity
BR112019003007A2 (en) neuropathic topical therapy with cariopylene
WO2018129507A3 (en) Generation of airway epithelial organoids from human pluripotent stem cells
WO2014082514A1 (en) Method for initiating stem cells of mammals and use of chlorine dioxide in preparation of drug for initiating stem cells of mammals
CN104922130A (en) Gel for treating herpes zoster and preparation method thereof
US11007178B2 (en) Methods and uses of Nampt activators for treatment of diabetes, cardiovascular diseases, and symptoms thereof
CN105287846A (en) Application of Shanhaidan Yujin injection in atomizing inhalation, spray bottle aerosol and rectal administration and method
BR0208962A (en) Method for releasing in vivo a chimeric oligonucleotide into target cells of a human or animal tissue, to treat a disease, to obtain an animal model, to select cosmetic or pharmaceutical compounds, to treat a human host having retinopathy and to treat a host human or animal having ocular neovascularization, chimeric alligonucleotide, pharmaceutical composition, animal model, and use thereof
WO2020170033A3 (en) Method for treatment of moderate to severe erythema symptoms in rosacea patients
WO2023156807A3 (en) Prevention and treatment of diseases by modulating activity of mesenchymal stem cells with p62 (sqstm1)-encoding vector and pharmaceutical formulations containing p62 (sqstm1) proteins
ES2927928T3 (en) Use of an antimicrobial composition
CN103735496A (en) Compound nasal gel for treating allergic rhinitis and preparing method thereof
CN110090207A (en) Application and its pharmaceutical composition of the sodium vedproate in the drug that preparation inhibits glial scar to be formed
CN100402039C (en) Hair growth promoting liquid
RU2391108C1 (en) Method of treating chronic adenoiditis and tonsillitis in children
CA3199787A1 (en) Compositions and methods for preventing and protecting against damage in cells and tissues
CN104667262B (en) BFGF bovine basic fibroblast growth factor externally used solution
CN201782878U (en) Transdermal iontophoretic eyecup electrode
KR101893339B1 (en) Composition comprising GDF11 and uses thereof
CN103153312A (en) Piroxicam for prophylactically and therapeutically treating herpes infections
CN105311040A (en) Fructose diphosphate containing novel pharmaceutical composition injection for treating circulation system diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 202490856

Country of ref document: EA

Ref document number: AU2022441199

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2022926917

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022926917

Country of ref document: EP

Effective date: 20240429

ENP Entry into the national phase

Ref document number: 2022441199

Country of ref document: AU

Date of ref document: 20220927

Kind code of ref document: A